The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFκB pathway

Journal of Innate Immunity

Volumn 1, Issue 2, 2009, Pages 164-174

  Su, Jianmin ^a   Zhang, Tongli ^a   Tyson, John ^a   Li, Liwu ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Alternative pathway; Computational simulation; Innate immunity; IRAK M; NF B; Signaling

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HETERODIMER; HOMODIMER; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE M; INTERLEUKIN 6; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; I KAPPA B KINASE; IRAK3 PROTEIN, MOUSE; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME DEFICIENCY; ENZYME STABILITY; GENE DELETION; INNATE IMMUNITY; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DOWN REGULATION; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; DOWN-REGULATION; I-KAPPA B KINASE; IMMUNITY, INNATE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 77953432630     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000158541     Document Type: Article

References (36)

1. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.
2. Chen LF, Greene WC: Shaping the nuclear action of NF- kB. Nat Rev Mol Cell Biol 2004; 5:392-401.
3. Viatour P, Merville MP, Bours V, Chariot A: Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52.
4. Dunne A, O'Neill LA: The interleukin-1 re-ceptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003:re3.
5. Hacker H, Karin M: Regulation and function of IKK and IKK-related kinases. Sci STKE 2006:re13.
6. Dejardin E: The alternative NF-kB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006;72:1161-1179.
7. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z: IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999;274: 19403-19410.
8. Kobayashi K, Hernandez LD, Galan JE, Jane-way CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202.
9. Su J, Xie Q, Wilson I, Li L: Differential regulation and role of interleukin-1 receptor associated kinase-M in innate immunity signaling. Cell Signal 2007; 19:1596-1601.
10. Li H, Cuartas E, Cui W, Choi Y, Crawford TD, Ke HZ, Kobayashi KS, Flavell RA, Vig-nery A: IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J Exp Med 2005; 201: 1169-1177.
11. Balaci L, Spada MC, Olla N, Sole G, Loddo L, Anedda F, Naitza S, Zuncheddu MA, Mas-chio A, Altea D, Uda M, Pilia S, Sanna S, Ma-sala M, Crisponi L, Fattori M, Devoto M, Do-ratiotto S, Rassu S, Mereu S, Giua E, Cadeddu NG, Atzeni R, Pelosi U, Corrias A, Perra R, Torrazza PL, Pirina P, Ginesu F, Marcias S, Schintu MG, Giacco GS, Manconi PE, Maler-ba G, Bisognin A, Trabetti E, Boner A, Pescollderungg L, Pignatti PF, Schlessinger D, Cao A, Pilia G: IRAK-M is involved in the pathogenesis of early-onset persistent asthma. Am J Hum Genet 2007;80:1103-1114.
12. Su J, Richter K, Zhang C, Gu Q, Li L: Differential regulation of interleukin-1 receptor associated kinase 1 (IRAK1) splice variants. Mol Immunol 2007;44:900-905.
13. Huang Y, Li T, Sane DC, Li L: IRAK1 serves as a novel regulator essential for lipopolysac-charide-induced interleukin-10 gene expression. J Biol Chem 2004;279:51697-51703.
14. Xiao G, Harhaj EW, Sun S-C: NF-KB-induc-ing kinase regulates the processing of NF-kB2 p100. Mol Cell 2001;7:401-409.
15. Oganesyan G, Saha SK, Guo B, He JQ, Sha-hangian A, Zarnegar B, Perry A, Cheng G: Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006;439:208-211.
16. Hayden MS, Ghosh S: Signaling to NF-kB. Genes Dev 2004;18:2195-2224.
17. O'Neill LA: The interleukin-1 receptor/Tolllike receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2000:RE1.
18. Covert MW, Leung TH, Gaston JE, Baltimore D: Achieving stability of lipopolysac-charide-induced NF-kB activation. Science 2005;309:1854-1857.
19. Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A: IkBe provides negative feedback to control NF- kB oscillations, signaling dynamics, and inflammatory gene expression. J Cell Biol 2006; 173:659-664.
20. Donn RP, Ray DW: Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004; 182:1-9.
21. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G: Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem 2007;282:3688-3694.
22. Qing G, Qu Z, Xiao G: Stabilization of ba-sally translated NF-KB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kB2 p100. J Biol Chem 2005;280:40578-40582.
23. Zarnegar B, Yamazaki S, He JQ, Cheng G: Control of canonical NF-kB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008; 105:3503-3508.
24. Wang RP, Zhang M, Li Y, Diao FC, Chen D, Zhai Z, Shu HB: Differential regulation of IKKα-mediated activation of IRF3/7 by NIK. Mol Immunol 2008; 45:1926-1934.
25. Choudhary S, Lu M, Cui R, Brasier AR: Involvement of a novel Rac/RhoA guanosine triphosphatase-nuclear factor-KB inducing kinase signaling pathway mediating angiotensin IIinduced RelA transactivation. Mol Endocrinol 2007;21:2203-2217.
26. Ishii KJ, Akira S: Toll-like receptors and sepsis. Curr Infect Dis Rep 2004;6:361-366.
27. West MA, Heagy W: Endotoxin tolerance: a review. Crit Care Med 2002;30:S64-S73.
28. Li L, Cousart S, Hu J, McCall CE: Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J Biol Chem 2000;275:23340-23345.
29. Cuschieri J, Bulmus V, Gourlay D, Garcia I, Hoffman A, Stayton P, Maier RV: Modulation of macrophage responsiveness to lipo-polysaccharide by IRAK-1 manipulation. Shock 2004;21:182-188.
30. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA, Standiford TJ: Sepsis-induced suppression of lung innate im-munity is mediated by IR AK-M. J Clin Invest 2006;116:2532-2542.
31. Nakayama K, Okugawa S, Yanagimoto S, Kitazawa T, Tsukada K, Kawada M, Kimura S, Hirai K, Takagaki Y, Ota Y: Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 2004;279: 6629-6634.
32. Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I, Wieckiewicz J, Zembala M: Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 2003;74:1094-1101.
33. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombach-er F, Borrello I, Zanovello P, Bicciato S , Bron-te V: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-2790.
34. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW: Monocyte/macrophage infiltration in tumors: modulators of angiogen-esis. J Leukoc Biol 2006;80:1183-1196.
35. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuen-tes-Prior P, Escoll P, Baos R, Caveda L, Garcia F, Arnalich F, Lopez- Collazo E: Tu mor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 2005;174:3032-3040.
36. Xie Q, Gan L, Wang J, Wilson I, Li L: Loss of the innate immunity negative regulator IR AK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 2007;44:3453-3461.